SOFT - TIAFT 1998 Poster Session 4 Friday October 9, 1998

Victor P. Uralets, Paul A. Gillette

Quest Diagnostics, Inc., 7470 Mission Valley Road, San Diego, CA 92108, USA

Recently, in November 1997, in addition to the previous appearance of 4-androsten-3,17-dione (1), as a nutritional supplement, two other anabolic steroids, 4-androsten-3,17-diol (2) and 19-nor-4-androsten-3,17-dione (3), became legally available over-the-counter in the United States. Their impact on urinary steroid profiles will be presented for males with different patterns of testosterone to epitestosterone (T/E) ratios.

Steroid 2, being a precursor of testosterone and other androgens, behaves similarly to 1, causing a brief abnormal increase (100 times) of the major urinary steroids: testosterone, epitestosterone, androsterone, etiocholanolone. Steroid 2, like 1, causes temporary increase of T/E for all but low T/E men. 2 undergoes conversion into numerous specific metabolites as well, especially into 3a- and 3b-ol-4-androsten-17-ones and 1.

Steroid 3, converting into nandrolone, appears in urine mainly as 19-norandrosterone and 19-noretiocholanolone, reaching concentrations in the first voids as high as 100,000 ng/mL. After a single oral dose of 50 mg, these remain detectable for at least 7 days and up to 10 days. 19-Nortestosterone and dehydrometabolites are well detectable during the first day of excretion. "Asian" men with low T/E metabolize 3 into the same main products as others do with one exception: 19-norepitestosterone appears in urine as a main intermediate metabolite, whereas for Caucasians 19-nortestosterone is a major.

Albuquerque logo
Previous Abstract
Friday Index

TIAFT '98 Homepage

TIAFTnet Homepage

Albuquerque logo
Next Abstract

Further information: or
TIAFT & CBFT 1995 - 1997 All Rights Reserved